SCHEDULE: Deep Track Capital Discloses Definium Therapeutics Stake

Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin have jointly reported beneficial ownership of 3,000,000 shares, representing 3.01% of Definium Therapeutics, Inc. common stock as of March 31, 2026.

Summary

• Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin have filed a Schedule 13G, indicating their beneficial ownership of Definium Therapeutics, Inc. common stock.
• As of March 31, 2026, the reporting persons collectively beneficially own 3,000,000 shares of common stock.
• This ownership represents 3.01% of the total outstanding common shares.
• The filing indicates shared voting and dispositive power over these shares.
• The total number of outstanding common shares used for this calculation was 99,698,129 as of February 19, 2026, based on the issuer's 10-K filing.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. It reports a significant ownership stake but provides no operational or financial performance data for Definium Therapeutics, making it purely an informational disclosure regarding shareholding.

Positives

• Significant stake reported by Deep Track Capital, indicating investor confidence or strategic interest in Definium Therapeutics.
• The reporting persons have shared voting and dispositive power, suggesting a coordinated investment strategy.

Negatives

• The filing does not contain any negative financial or operational information about Definium Therapeutics; it solely reports ownership.

Risks

• The filing does not explicitly mention any risks related to Definium Therapeutics. The primary risk for investors would be the general market and company-specific risks associated with holding equity in a publicly traded company, which are not detailed here.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding the company's future performance.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors accumulating significant stakes. This filing indicates Deep Track Capital's substantial interest in Definium Therapeutics, potentially signaling a belief in the company's future prospects or a strategic investment position within the biotechnology sector.

Stakeholder Impact

• Shareholders: The filing informs existing shareholders about a significant institutional investor's stake, which could influence market perception and trading activity.
• Management: Definium Therapeutics' management is aware of Deep Track Capital's ownership level, which may be a factor in future strategic discussions or board composition considerations.
• Creditors: No direct impact is indicated, as the filing pertains to equity ownership.

Next Steps

• Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin will continue to monitor their investment in Definium Therapeutics, Inc.
• Future amendments to this Schedule 13G will be filed if there are changes in beneficial ownership.

Key Dates

Keywords

Definium Therapeutics, Schedule 13G, Deep Track Capital, Beneficial Ownership, Common Stock, SEC Filing, Investment, Shareholder